drugset
drugset / Trial / NCT05479240

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

NCT05479240 ↗

Phase 2 Not yet recruiting 94 enrolled Fujian Cancer Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy of Neoadjuvant Chemoradiotherapy Combined With/without Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Timeline

Start
2023-09-01
Primary completion
2025-06-01
Completion
2028-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Background Capecitabine Small molecule 1000 mg/m2 —
Background Oxaliplatin Small molecule 130 mg/m2 —

Indications

No indication recorded.